Guaifenesin
drugOn this page
Also known as AmonidronCVT-2534FamelFranolyn chestyGlyceryl guaiacolateGuaiacol glyceryl etherGuaifenesin component of flowtussGuaifenesin component of hycofenixGuaifenesin component of mucinex dGuaifenesin component of mucinex dmGuaifenesin component of obredonGuaifenesin component of xtrelusGuaifenesinaGuaifenesineGuaifensinGuaiphenesinGecolateGlycerol guaiacolateHustosil
Summary
Guaifenesin (CHEMBL980) is an approved small molecule (ATC R05CA03); indicated across 7 conditions including sinusitis and respiratory tract infectious disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: R05CA03
- Indications: 7 conditions
- Clinical trials: 17
- Chemistry: 198.22 Da · C10H14O4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL980 |
| Name | Guaifenesin |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 3516 |
| ATC | R05CA03 |
| Molecular formula | C10H14O4 |
| Molecular weight | 198.22 |
| InChIKey | HSRJKNPTNIJEKV-UHFFFAOYSA-N |
SMILES: COC1=CC=CC=C1OCC(CO)O
IUPAC name: 3-(2-methoxyphenoxy)propane-1,2-diol
Also known as: Amonidron, CVT-2534, Famel, Franolyn chesty, Glyceryl guaiacolate, Guaiacol glyceryl ether, Guaifenesin, Guaifenesin component of flowtuss, Guaifenesin component of hycofenix, Guaifenesin component of mucinex d, Guaifenesin component of mucinex dm, Guaifenesin component of obredon
Patent coverage: 4,390 distinct patent families (14,686 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 14,674 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Type-1 angiotensin II receptor.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| sinusitis | 4 | MONDO:0005961 | EFO:0007486 |
| respiratory tract infectious disorder | 3 | MONDO:0024355 | MONDO:0024355 |
| common cold | 2 | MONDO:0005709 | EFO:0007214 |
4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 17.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 6 |
| PHASE2 | 4 |
| PHASE3 | 3 |
| PHASE4 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00377403 | PHASE4 | COMPLETED | Treatment of Acute Sinusitis |
| NCT01202279 | PHASE4 | COMPLETED | Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI |
| NCT01085721 | PHASE3 | UNKNOWN | Comparison Between Dexchlorpheniramine and Dexchlorpheniramine/Pseudoephedrine/Guaifenesin in Respiratory Infections |
| NCT01119534 | PHASE3 | UNKNOWN | Comparative Efficacy of the Suppository Versus Guaiacol Suppository Versus Guaifenesin Syrup in Pediatric Patients With Cough Due the Infectious Origin |
| NCT01537081 | PHASE2/PHASE3 | COMPLETED | Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections |
| NCT01576809 | PHASE3 | COMPLETED | Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Syrup in Patients Suffering a Upper Respiratory Tract Infection (URTI) |
| NCT00000752 | PHASE2 | WITHDRAWN | Preventing Frequent Sinus Infections in HIV-Infected Patients |
| NCT01046136 | PHASE2 | COMPLETED | Mucinex Exploratory Cold Study |
| NCT01114581 | PHASE2 | COMPLETED | Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection |
| NCT01364467 | PHASE2 | COMPLETED | The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study |
| NCT00902707 | PHASE1 | COMPLETED | Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung |
| NCT01062256 | Not specified | COMPLETED | Study of Count Coughs in Subjects With Acute Upper Respiratory Tract Infections |
| NCT01562548 | Not specified | COMPLETED | Exploratory Efficacy Study of Guaifenesin in Upper Back Pain |
| NCT02069665 | Not specified | COMPLETED | Effectiveness Study of Integrative Treatment for Pediatric Pneumonia |
| NCT02879981 | Not specified | COMPLETED | A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis |
| NCT02902640 | Not specified | COMPLETED | A Non-Interventional Safety Study of Balsamic Bactrim |
| NCT07398924 | Not specified | COMPLETED | Vaginal Estradiol and Oral Guaifenesin in Clomiphene Ovulation Induction |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: sinusitis, respiratory tract infectious disorder